Fundamental Data for IDMI

IDM is a biopharmaceutical company focused on the development of innovative products that activate the immune system to treat cancer and infectious disease. IDM is currently developing three types of products: the first is designed to destroy cancer cells by activating innate immunity, the second to prevent tumor recurrence by triggering a specific adaptive immune response, and the third to treat chronic infectious disease with therapeutic vaccines.

# Employees: 23

Address: 9 Parker Suite 100,Irvine,,USA

Phone: 949 470-4751

Fax: 949 470-6470

Website: www.idm-biotech.com

Email:

Sector: Medical

Industry: MED-DRUGS

Executive Officers

Timothy P. Walbert (Persi.; C.E.O.)

Robert J. De Vaere (Sr. V.P.; C.F.O.; Princ. Acttg. Off.)

Robert Beck M.D. (Dir.)

Jean Deleage Ph.D (Dir.)

Sylvie Gr??goire Pha. (Dir.,)

Dividend

Ex-Dividend Date: N/A

Annual Dividend: N/A

Current Dividend Yield: N/A

Dividend Paid (3 months): N/A

Indicated Dividend: N/A

Earnings

Last Earnings Date: 3/31/2009

Next Earnings Date(Expected): 8/6/2009

Mean EPS (Next Qtr): ($0.01)

Mean EPS (Year): ($0.01)

Mean Estimate(Long Term): ($0.01)

P/E Ratio(Based on EPS estimate): -0.010

Number of Estimates: 0

Shares Performance

Period	IDMI	Compare to S&P
YTD	66.46 %	63.21 %
4 Weeks	0.77 %	-2.98 %
12 Weeks	26.44 %	11.99 %

Shares Information

Analyst Coverage: N

Avg Volume: 190243

Shares Outstanding: 25M

Market Cap: $0.07B

52 Week High: $3.63

52 Week Low: $1.45

P/E Ratio: -0.010

PEG Ratio: -0.010

Split: On 8/16/2005 IDMI split by factor of 0.140

Earnings Performance

EPS Growth in Last Quarter: -185.71 %

EPS Growth in Last Year: 47.37 %

Sales Growth in Last Quarter: -98.62 %

Sales Growth in Last Quarter: -99.83 %

Financials

Qtr Book Value: $19.30

Cash Flow/Share: ($0.01)

Change in Payout Ratio: -0.010

Price/Sales: 89.100